GlassScriptPhysician profile
Taral B Patel
NPI 1750743472
$8,642.73
in general payments reported to CMS, 2019-2025
24 companies · $782 in 2025
The $782 reported for 2025 was more than what 93% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $255 · 2021: $206 · 2022: $407 · 2023: $375 · 2024: $6,499 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $5,490 · Food and Beverage: $1,939 · Travel and Lodging: $205 · Consulting Fee: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $5,490.00 |
| Food and Beverage | $1,939.00 |
| Travel and Lodging | $205.39 |
| Consulting Fee | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $5,717.09 | 2024 | Monoferric |
| Abbvie INC. | $973.03 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $500.83 | 2020-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $351.43 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $176.88 | 2023-2025 | Omvoh, Zepbound |
| Qol Medical, LLC | $143.31 | 2021-2024 | Sucraid, Sucraid |
| Pfizer INC. | $133.85 | 2020 | |
| Blueprint Medicines Corporation | $118.97 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $82.53 | 2020-2025 | Caldolor |
| Ardelyx, INC. | $82.00 | 2023-2024 | Ibsrela |
| Celltrion USA INC. | $78.56 | 2024-2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $70.67 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $35.34 | 2023-2024 | Dupixent |
| Ucb, INC. | $22.58 | 2019 | |
| Genzyme Corporation | $18.39 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $17.21 | 2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.14 | 2023 | Cyltezo |
| Aimmune Therapeutics, INC. | $16.19 | 2023 | |
| Janssen Pharmaceuticals, INC | $15.00 | 2021 | |
| Acelrx Pharmaceuticals, INC. | $14.91 | 2019 | |
| Daiichi Sankyo INC. | $14.84 | 2020 | |
| Chiesi USA, INC. | $14.72 | 2022 | |
| Intercept Pharmaceuticals, INC. | $14.67 | 2019 | |
| Csl Behring | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taral Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.